Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03275688 · ClinicalTrials.gov registry record

NanoSpectrometer Biomarker Discovery and Confirmation Study

A clinical trial, sponsored by Johns Hopkins University.

Terminated
Registry status
332
Enrollment target

NCT03275688: Clinical Trial study, sponsored by Johns Hopkins University.

NCT03275688 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 332 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03275688 was terminated before completion, sponsored by Johns Hopkins University.

TERMINATED
Registry status
332 participants
Enrollment target

Study Summary

This study will evaluate exhaled volatile organic compounds (VOC's) in the breath of participants with stage 1 lung cancer, their house-mates, and matched controls. The goal of the study is to identify VOC fingerprints that are only detectable in those with stage 1 lung cancer.

Primary Outcome

Volatile organic compounds will be measured between the cases and both types of controls. We will report the different volatile organic compound fingerprints that are present in cases and not in controls.

Interventions

  • DIAGNOSTIC_TEST Breath Analysis

Trial Details

FieldValue
Enrollment Target 332 participants
Start Date 2017-09-05
Est. Completion 2020-07-06
Johns Hopkins University

1,448 total trials

Why NCT03275688 stopped before completion

NCT03275688 is an observational study that tracks outcomes without assigning an intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which Breath Analysis is the first listed.

NCT03275688 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03275688 about?

NCT03275688 is a clinical study titled "NanoSpectrometer Biomarker Discovery and Confirmation Study". This study will evaluate exhaled volatile organic compounds (VOC's) in the breath of participants with stage 1 lung cancer, their house-mates, and matched controls. The goal of the study is to identify VOC fingerprints that are only detectable in those with stage 1 lung cancer.

What is the current status of trial NCT03275688?

This trial is currently terminated. The enrollment target is 332 participants. The study started on 2017-09-05. Estimated completion is 2020-07-06.

What interventions are being tested in trial NCT03275688?

The interventions under investigation include: Breath Analysis (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03275688?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174121 · 332 participants · Phase 2

    Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  • NCT02605785 · 332 participants · NA

    A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

  • NCT04894006 · 332 participants · NA

    Dementia Family Caregiver Study

  • NCT05130606 · 332 participants · NA

    CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03275688, the US trial registry maintained by the National Library of Medicine. NCT03275688 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.